ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the advancement of
immunomodulatory therapies for common inflammatory conditions,
announced that the Company will be hosting a webinar and conference
call today at 4:30pm EST to provide
an update on clinical and regulatory progress in osteoarthritis of
the knee.
Webinar Details
Date/Time: March 2, 2022,
at 4:30 pm EST
Webinar
Link: https://event.on24.com/wcc/r/3574331/964B6C5B80DB9EFD05CA55D0977BD0D5
Canada dial-in number (Toll
Free): 1 833 950 0062
Canada dial-in number
(Local): 1 226 828 7575
United States (Toll Free):
1 833 927 1758
United States (Local): 1
646 904 5544
All other locations: +1 929 526 1599
Access code: 644727
*Participants will need to enter the participant access code
before being met by an operator
In order to submit questions, participants must have Internet
connectivity, as questions will only be addressed via the
webcast. The conference call line will be in listen-only
mode.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release and the webinar that
are not historical fact, and that relate to future plans or events,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical trials and
decisions and changes in business conditions and similar events,
the ability to receive regulatory approval to conduct clinical
trials, that Ampion may be used to treat ARDS induced by COVID-19,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-host-a-conference-call-and-webinar-301493693.html
SOURCE Ampio Pharmaceuticals, Inc.